01—Abstract
Summary
Summary of the 10-K filed February 17, 2012. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation's (BSX) 2011 Form 10-K highlights a year of strategic repositioning and operational adjustments.
The company reported net sales of $7.62 billiona, a slight decrease from the prior year, impacted by the divestiture of its Neurovascular business. Despite the sales decline, adjusted net income remained robust, reflecting successful cost-containment measures and restructuring initiatives aimed at improving operational efficiency and profitability. The company continued to invest in research and development, focusing on innovation across its key business segments, including Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, and Peripheral Interventions.
Key financial and operational themes for 2011 include managing pricing pressures in core markets like coronary stents and CRM, investing in emerging markets, and navigating a complex regulatory and reimbursement environment. The company made significant strides in debt reduction, improving its credit ratings, and repurchased a substantial amount of its common stock. Despite facing challenges such as competition and evolving healthcare policies, Boston Scientific emphasized its commitment to innovation and delivering value to patients and shareholders through its diversified portfolio of less-invasive medical devices.
02—Key points
Key Highlights
- Net sales for 2011 were $7.62 billion, a 2% decrease from $7.81 billion in 2010, primarily due to the divestiture of the Neurovascular business and declines in Interventional Cardiology and CRM segments, partially offset by favorable foreign currency fluctuations.
- Reported net income was $441 million ($0.29 per share) in 2011, compared to a net loss of $1.065 billion (-$0.70 per share) in 2010. Adjusted net income (excluding special items) was $1.018 billion ($0.67 per share) in 2011, compared to $1.051 billion ($0.69 per share) in 2010.
- The company recorded a significant goodwill impairment charge of $697 million in Q1 2011 related to its U.S. Cardiac Rhythm Management (CRM) business, reflecting market pressures and revised revenue projections.
- Boston Scientific completed the sale of its Neurovascular business to Stryker Corporation in January 2011 for $1.5 billion in cash, contributing to a substantial debt reduction.
- The company continued its restructuring efforts, including the 2011 Restructuring plan, 2010 Restructuring plan, and Plant Network Optimization program, aimed at improving operational effectiveness, efficiency, and competitiveness.
- Significant investments were made in strategic growth areas, including acquisitions in structural heart therapy (Sadra Medical, Inc.) and atrial fibrillation (Atritech, Inc.), and continued expansion in emerging markets like China, Brazil, and India.
- Debt levels were reduced by $1.177 billion in 2011, and the company's credit ratings were maintained at investment grade by major agencies, reflecting improved financial fundamentals.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Boston Scientific Corp kept $0.06.
- Revenue$7.62B100.0%
- Cost of revenue−$2.66B34.9%
- Gross profit$4.96B65.1%
- Operating costs−$4.06B53.3%
- Operating income$904.0M11.9%
- Interest, other & tax−$463.0M6.1%
- Net income$441.0M5.8%
Where FY2011 revenue went
$7.62B- Cost of revenue: $2.66B, 35% of revenue
- SG&A: $2.49B, 33% of revenue
- Other operating costs: $1.57B, 21% of revenue
- Net income: $441.0M, 5.8% of revenue
- Interest, other & tax: $463.0M, 6.1% of revenue
Kept 5.8% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 17, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $7.62B$7.81B | −2.4% |
| Cost of Revenue | $2.66B$2.60B | +2.3% |
| Gross Profit | $4.96B$5.21B | −4.7% |
| SG&A Expenses | $2.49B$2.58B | −3.6% |
| Operating Expenses | $4.06B$5.86B | −30.8% |
| Operating Income | $904.00M-$656.00M | +237.8% |
| Interest Expense | $281.00M$393.00M | −28.5% |
| Net Income | $441.00M-$1.06B | +141.4% |
| EPS (Basic) | $0.29$-0.70 | +141.4% |
| EPS (Diluted) | $0.29$-0.70 | +141.4% |
| Shares Outstanding (Basic) | 1.51B1.52B | −0.6% |
| Shares Outstanding (Diluted) | 1.52B1.52B | +0.1% |
05—Questions
Frequently Asked Questions
What were Boston Scientific's primary revenue drivers and challenges in 2011?
Boston Scientific's primary revenue drivers in 2011 were its Interventional Cardiology, Cardiac Rhythm Management (CRM), and Endoscopy segments. Key challenges included pricing pressures in the coronary stent and CRM markets, competitive intensity, and the impact of healthcare reform and evolving reimbursement policies. The divestiture of the Neurovascular business also impacted overall sales figures.
How did the company manage its debt and financial position in 2011?
In 2011, Boston Scientific significantly reduced its total debt by $1.177 billion, repaying $1.0 billion of its term loan and $250 million of senior notes. These actions, combined with improved operational performance and product portfolio strength, led to credit rating upgrades from Fitch and Moody's, maintaining investment-grade status and strengthening its financial flexibility.
What significant restructuring or strategic initiatives were undertaken in 2011?
In 2011, Boston Scientific continued to implement its strategic plan, which included the divestiture of its Neurovascular business, several strategic acquisitions to bolster growth areas like structural heart therapy and deep-brain stimulation, and ongoing restructuring initiatives aimed at enhancing operational efficiency and reducing costs. The company also increased investments in emerging markets to capture growth opportunities.
What was the impact of goodwill impairment charges on the company's financial statements?
In 2011, Boston Scientific recorded a significant goodwill impairment charge of $697 million related to its U.S. Cardiac Rhythm Management (CRM) reporting unit. This was driven by market pressures, including reduced market size estimates for ICDs, lower projected results, and increased competition, which impacted the unit's fair value. While a non-cash charge, it significantly affected the reported net income for the year.
06—Continue